Scynexis Inc
$ 1.02
0.99%
14 Apr - close price
- Market Cap 45,110,500 USD
- Current Price $ 1.02
- High / Low $ 1.08 / 1.01
- Stock P/E N/A
- Book Value 1.13
- EPS -0.17
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.16 %
- 52 Week High 1.31
- 52 Week Low 0.56
About
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
Analyst Target Price
$3.47
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-01 | 2026-03-05 | 2025-11-05 | 2025-08-13 | 2025-05-06 | 2025-03-26 | 2024-11-11 | 2024-08-08 | 2024-05-08 | 2024-02-07 | 2023-11-13 | 2023-08-14 |
| Reported EPS | 0 | 0.25 | -0.17 | -0.14 | -0.11 | -0.09 | -0.06 | -0.3 | 0.01 | -0.39 | -0.04 | 2.46 |
| Estimated EPS | 0.1267 | 0.1267 | -0.2 | -0.2 | -0.2 | -0.02 | -0.07 | -0.2 | -0.2 | -0.2 | -0.15 | 1.55 |
| Surprise | -0.1267 | 0.1233 | 0.03 | 0.06 | 0.09 | -0.07 | 0.01 | -0.1 | 0.21 | -0.19 | 0.11 | 0.91 |
| Surprise Percentage | -100% | 97.3165% | 15% | 30% | 45% | -350% | 14.2857% | -50% | 105% | -95% | 73.3333% | 58.7097% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SCYX
2026-04-13 11:10:08
SCYNEXIS INC (NASDAQ:SCYX) has been identified as a stock that fits both Mark Minervini's Trend Template and high-growth momentum investing criteria. This indicates the company shows strong, continuous price movements and improving fundamental performance, driven by significant revenue and EPS growth, and a recent shift to profitability. The analysis suggests SCYX presents a compelling case for investors seeking growth, while also noting the importance of further due diligence and risk management.
2026-04-02 12:10:25
SCYNEXIS CEO David Angulo Gonzalez acquired 108,695 shares of common stock and matching warrants through a private placement that closed on April 1, 2026. The combined purchase price was $0.92 per share and warrant unit. Following these transactions, he directly owns 1,357,126 shares of SCYNEXIS common stock.
2026-04-02 12:10:25
Scynexis INC CEO David Angulo Gonzalez purchased 108,695 shares for approximately $100,000, bringing his total direct ownership to over 1.3 million shares. This transaction was part of a private placement that also included warrants, and it follows a strong year-to-date performance for the stock. Analysts maintain a positive outlook for SCYNEXIS, with price targets ranging from $3 to $4.
2026-04-01 06:09:58
Poxel SA has announced the sale of its clinical-stage drug candidate PXL770 to SCYNEXIS, Inc. for a potential total of $196 million. Poxel will receive an $8 million upfront payment, with additional payments tied to development and commercial milestones. This divestment aims to strengthen Poxel's financial position, allowing them to focus on their TWYMEEG® and PXL065 products.
2026-04-01 04:09:42
Poxel has announced the sale of its clinical-stage drug candidate, PXL770, to Scynexis for a total of up to $196 million. This agreement includes an $8 million upfront payment and up to $188 million in future clinical and commercial milestone payments. PXL770, renamed SCY-770, targets autosomal dominant polycystic kidney disease (ADPKD) and Scynexis plans to initiate a Phase 2 study in late 2026.
2026-03-31 19:39:46
SCYNEXIS (SCYX) has extended its cash runway into mid-2029 by securing a $40 million PIPE financing and acquiring global rights to SCY-770, a Phase 2-ready asset for Autosomal Dominant Polycystic Kidney Disease (ADPKD). This strategic move, which includes an $8 million upfront payment and potential milestones, repositions the company with a new rare-disease focus. SCYNEXIS plans to initiate a Phase 2 study for SCY-770 in Q4 2026 with an early efficacy readout expected in the second half of 2027, while continuing to advance other assets.
